This webinar covered
Since January 2023, the RNA and Gene Therapy landscapes have been nothing but dynamic. Overall, 21 drugs entered the clinic for the first time, 9 preclinical and 9 clinical drugs were discontinued, and 2 drugs (VYJUVEK and Elevidys) were approved within the gene therapy space, while there have been 79 therapies entering the clinic across the mRNA, oligonucleotide, and gene editing space.
Navigating these quickly evolving landscapes makes access to accurate and comprehensive information paramount to informed decision-making. Therefore, to conclude our landscape review series, and to explore the array of data available across the RNA and Gene Therapy landscapes, our research experts explored the drug and trial report data across both modalities and provide further exclusive insights. Key aspects included:
- A mid-year review of the RNA landscape, focusing on messenger RNAs, oligonucleotides, and guide RNA-mediated gene editing
- An exploration of the current Gene Therapy drug and trial landscape, covering the 2000+ drugs and the 800+ trials tracked on Beacon
- A picture of what we can likely expect ahead based on recent approvals and late-stage activity